Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Genetics (ATOS) today and set a price target of $5. The company’s shares opened today at $1.74, close to its 52-week low of $0.80.
McCarthy commented:
“Atossa announced that the preliminary results (PK, tolerability, safety) reported in 3Q18 in the P1 study of topical Endoxifen in male healthy subjects are now final. The company is awaiting the completion of an ongoing P2 study in women with mammographic breast density (MBD, expected 2Q19) to determine the next steps clinically for developing topical Endoxifen in men with breast health issues, including gynecomastia.”
According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -8.9% and a 28.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Atossa Genetics with a $5 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.68 and a one-year low of $0.80. Currently, Atossa Genetics has an average volume of 441.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests.
